.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The COLCOT randomized trial evaluated low-dose colchicine started soon after myocardial infarction. Compared with placebo, colchicine reduced the risk of a composite cardiovascular endpoint, driven particularly by reductions in stroke and urgent hospitalization for angina leading to coronary revascularization. The study added evidence that residual inflammatory risk may be a therapeutic target after acute coronary syndrome. For physicians, the practical value lies less in routine colchicine for every post-MI patient and more in understanding the evolving role of inflammation in secondary prevention. Standard therapies—antiplatelets, statins, beta-blockers when indicated, renin–angiotensin system therapy and lifestyle intervention—remain central. Colchicine also has tolerability and drug-interaction considerations, especially gastrointestinal effects and interactions with strong CYP3A4 or P-glycoprotein inhibitors. The trial therefore opens a useful discussion about how newer anti-inflammatory strategies may complement established risk-factor management in selected patients.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The COLCOT randomized trial evaluated low-dose colchicine started soon after myocardial infarction. Compared with placebo, colchicine reduced the risk of a composite cardiovascular endpoint, driven particularly by reductions in stroke and urgent hospitalization for angina leading to coronary revascularization. The study added evidence that residual inflammatory risk may be a therapeutic target after acute coronary syndrome. For physicians, the practical value lies less in routine colchicine for every post-MI patient and more in understanding the evolving role of inflammation in secondary prevention. Standard therapies—antiplatelets, statins, beta-blockers when indicated, renin–angiotensin system therapy and lifestyle intervention—remain central. Colchicine also has tolerability and drug-interaction considerations, especially gastrointestinal effects and interactions with strong CYP3A4 or P-glycoprotein inhibitors. The trial therefore opens a useful discussion about how newer anti-inflammatory strategies may complement established risk-factor management in selected patients.
4 weeks back
Discover how catalytic nanozymes redefine autoimmune disease therapy by establishing a physiological redox set-point to restore immune tolerance without broad immunosuppression.
Last week
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
3 weeks back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
3 weeks back
